IOL Chemicals & Pharmaceuticals Ltd (IOLCP)
₹213.04
Mkt cap
₹5,869 Cr
P/E ratio
33.20
P/B
3.48
Div yield
0.50%
ROE
8.42%
ROCE
11.30%
EPS (TTM)
₹6.42
Book value
₹61
52W range
68–215
Sector
Healthcare
Price history
Previous close
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. [1] It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%. [2]
NSE IOLCPBSE 524164
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−0.91% from high₹213
₹68+212.33% from low₹215
Current
₹213.04
Prev close
₹199.95
Day
+6.55%
Price performance
1D
+7.53%
1W
+11.00%
1M
+28.09%
3M
+61.85%
6M
+206.44%
1Y
+130.84%
YTD
+153.53%
Financials
Revenue, profit & margin
P/E ratio
33.2×
IOLCP is 2% below the sector median of 34.0×
IOLCP33.2×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 563 | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 | |
| Expenses | 490 | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 | |
| Operating Profit | 73 | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 93 | 104 | |
| OPM % | 13% | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% | |
| Other Income | 7 | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 | |
| Interest | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 | |
| Depreciation | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 | |
| Profit before tax | 62 | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 | 28 | 71 | 87 | |
| Tax % | 25% | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% | |
| Net Profit | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 | 21 | 53 | 64 | |
| EPS in Rs | 1.57 | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.70 | 1.08 | 1.16 | 1.02 | 0.70 | 1.81 | 2.20 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.90% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 10 Aug '26 |
| Earnings day | −1.90% |
| +1 day | −2.21% |
| +5 days | −3.91% |
| +15 days | +15.39% |
| +30 days | — |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202662.28%Promoter
Promoters62.28%4.80
FIIs4.87%3.15
DIIs0.43%0.41
Public32.41%8.37
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| IOLCP | ₹199.95 | 33.23 | 5,869 | 0.50% | 64 | +89.87% | 756 | +37.08% | 11.29% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts54
TranscriptNov 2024TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025PPTNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 2 Sep - IOLCP submitted 39th AGM voting results and scrutinizer report; all three resolutions passed on 2 September 2026.Shareholder Meeting / Postal Ballot-Outcome of AGM 2 Sep - 39th AGM held on 2 September 2026; all resolutions passed with requisite majority.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Aug - IOLCP to meet analysts/institutional investors on 3 September 2026 at Phillip Capital event.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 20 AugAnnouncement under Regulation 30 (LODR)-Newspaper Publication 18 Aug